UnitedHealthcare Limits Lab Test Reimbursement Across Medicaid and Other Lines
UnitedHealthcare will implement new reimbursement limits on five categories of lab tests — allergen testing, liver fibrosis testing, in vitro chemotherapy sensitivity assays, testosterone blood tests, and vitamin B12 testing — effective September 1, 2026. The policies apply across the company's commercial, ACA exchange, Medicare Advantage, and Medicaid product lines. UnitedHealthcare Medicaid plans will be affected by the same utilization management criteria being applied to other lines of business. The changes will affect laboratory providers billing UnitedHealthcare Medicaid plans and could impact member access to certain diagnostic tests.
State Medicaid agencies contracting with UnitedHealthcare MCOs should assess whether these reimbursement restrictions comply with state contract provisions on laboratory access and medical necessity criteria, particularly for populations with chronic conditions requiring routine lab monitoring.
Managed Care
You might also like